文献速递肝病消化道肿瘤与早癌

遗传学证据表明FGF21信号可减少问题性饮酒和酒精相关肝病

Genetic evidence that FGF21 signaling reduces problematic alcohol use and alcohol-related liver disease.
PubMed 文献 · J Hepatol · 2026-02-24

本研究利用UK Biobank、FinnGen、Million Veterans Program和GenomALC的GWAS数据,通过四层孟德尔随机化分析评估FGF21信号对问题性饮酒、酒精使用障碍、暴饮和酒精相关肝病的影响。结果显示遗传预测的较高FGF21蛋白水平与较低的问题性饮酒(β=-0.097)和酒精相关肝病风险(OR=0.79)相关,且效果完全由行为通路介导。肝FGF21表达升高还降低问题性饮酒(β=-0.245)和酒精相关肝病风险(OR=0.54),受体分析提示海马FGFR3和基底节KLB参与肝-脑轴。

要点

  • 遗传预测较高FGF21水平与较低问题性饮酒和酒精相关肝病风险相关。
  • FGF21效果完全由行为通路(减少饮酒、改善饮食)和基础代谢率增加介导。
  • 肝FGF21表达升高降低问题性饮酒和酒精相关肝病风险,优于PNPLA3和HSD17B13。

核心结论

  • 人类遗传学证据表明FGF21类似物通过行为和代谢通路减轻有害饮酒和酒精相关肝病。

研究设计与样本

  • 利用UK Biobank、FinnGen、Million Veterans Program和GenomALC的GWAS数据进行孟德尔随机化分析。
  • 四层评估包括多变量MR和中介分析、比较MR、受体聚焦MR和全表型MR(1022个特征)。

主要发现

  • 遗传预测较高FGF21蛋白水平与较低问题性饮酒相关(β=-0.097,95%CI -0.135至-0.059,p=6.13×10-7)。
  • 遗传预测较高FGF21蛋白水平与较低酒精相关肝病风险相关(OR=0.79,95%CI 0.638-0.987,p=0.038)。
  • 肝FGF21表达每升高1-SD降低问题性饮酒风险(β=-0.245,95%CI -0.409至-0.082,p=0.003)和酒精相关肝病风险(OR=0.54,95%CI 0.417-0.697,p=2.44×10-6)。
  • 海马FGFR3表达与酒精相关肝病风险降低相关(OR=0.909,95%CI 0.876-0.943,p=4.28×10-7)。
  • 全表型MR发现28个Bonferroni显著的保护性关联(例如痛风)。

临床怎么用

  • 支持FGF21类似物在酒精使用障碍和酒精相关肝病临床试验中的重定位。
  • 遗传分层可能优化患者选择以接受FGF21类似物治疗。
  • FGF21的安全性特征优于HSD17B13或PNPLA3靶点。

局限性

  • 结论基于欧洲 ancestry 遗传数据。
  • 结论依赖孟德尔随机化假设。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Fibroblast growth factor 21 (FGF21) analogs are in development for metabolic dysfunction-associated steatotic liver disease (MASLD), but their impact on problematic alcohol use (PAU), alcohol use disorder, binge drinking, and alcohol-related liver disease (ALD) is unknown. METHODS: We leveraged genome-wide association study data from the UK Biobank, FinnGen, Million Veterans Program, and GenomALC for PAU, alcohol use disorder, binge drinking, weekly drinks, and ALD. Our four-tier evaluation included: (1) multivariable Mendelian randomization (MR) and mediation with circulating FGF21 levels; (2) comparative MR of MASLD and ALD targets (PNPLA3, TM6SF2, HSD17B13) using liver fat and expression instruments; (3) receptor-focused MR of β-Klotho (KLB) and FGFR1/2/3 incorporating brain-region expression; and (4) a phenome-wide MR across 1,022 traits to assess safety. RESULTS: Genetically higher FGF21 protein levels were associated with lower PAU (β = -0.097, 95% CI -0.135 to -0.059, p = 6.13 × 10-7), fewer binge episodes, reduced drinking, and lower ALD risk (odds ratio [OR] = 0.79, 95% CI 0.638-0.987, p = 0.038). Multivariable MR and mediation attributed these effects entirely to behavioral pathways (reduced drinking, improved diet) and increased basal metabolic rate. In comparative MR, FGF21 - unlike PNPLA3, or HSD17B13 - reduced alcohol outcomes: a 1-SD rise in hepatic FGF21 expression reduced PAU (β = -0.245, 95% CI -0.409 to -0.082, p = 0.003) and ALD (OR = 0.54, 95% CI 0.417-0.697, p = 2.44×10-6) risk. Receptor analyses implicated hippocampal FGFR3 (OR = 0.909, 95% CI 0.876-0.943, p = 4.28 × 10-7) and basal ganglia KLB expression, supporting a liver-brain axis. Phenome-wide MR uncovered 28 Bonferroni-significant protective associations with higher FGF21 (e.g. gout). Hepatic FGF21 expression showed fewer on-target liabilities than HSD17B13 or PNPLA3. CONCLUSIONS: Human genetic evidence indicates that FGF21 analogs mitigate hazardous drinking and ALD via both behavioral and metabolic pathways. These findings distinguish FGF21 from other MASLD targets and highlight its potential for precision treatment of alcohol-related disorders. IMPACT AND IMPLICATIONS: This study leverages human genetic evidence to validate FGF21 - a liver-derived hormone currently in clinical trials for fatty liver disease - as a dual-action therapeutic that both curbs harmful drinking behaviors and protects against alcohol-related liver injury, addressing a critical therapeutic gap with limited existing pharmacotherapies. The results are important for clinicians and researchers seeking precision medicine strategies for alcohol use disorder and liver disease, as well as for patients who currently face limited treatment options. By pinpointing FGF21's behavioral and metabolic pathways and demonstrating a favorable safety profile, our findings support the repurposing of FGF21 analogs in clinical trials of alcohol use disorder and alcohol-related liver disease and suggest that genetic stratification could optimize patient selection for therapy. While these conclusions rely on European-ancestry genetic data and Mendelian randomization assumptions, they help inform future clinical studies, biomarker development, and policy efforts aimed at expanding treatment options for alcohol-related conditions.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Rosoff DB, Wagner-DeTurck J, Perlstein T, et al. Genetic evidence that FGF21 signaling reduces problematic alcohol use and alcohol-related liver disease. J Hepatol. 2026. PMID: 41747774. doi:10.1016/j.jhep.2026.01.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。